Comparison of Baseline versus Posttreatment Left Ventricular Ejection Fraction in @entity1 with @entity712 for Predicting Cardiovascular Outcome: Implications from Single-Center XXXX Cohort.

@entity1 @entity50067 @entity712 @entity697
AIMS: The prognostic values of left ventricular ejection fraction ( @entity50067 ) during @entity712 ( @entity712 ) with acute decompensation or after optimal treatment have not been extensively studied. We hypothesized that posttreatment @entity50067 has superior predictive value for long-term prognosis than @entity50067 at admission does. METHODS AND RESULTS: In Protocol 1, 428 @entity712 ( @entity697 ) @entity1 with @entity50067  <=35% in a tertiary medical center were enrolled and followed for a mean period of 34.7    10.8 months. The primary and secondary end points were all-cause mortality and @entity712 readmission, respectively. In total, 86 deaths and 240 @entity712 readmissions were recorded. The predictive values of baseline @entity50067 at admission and @entity50067 6 months posttreatment were analyzed and compared. The posttreatment LVEFs were predictive for future events (P = 0.01 for all-cause mortality, P < 0.001 for @entity712 readmission), but the baseline LVEFs were not. In Protocol 2, the outcomes of @entity1 with improved @entity50067 (change of @entity50067 : >= +10%), unchanged @entity50067 (change of @entity50067 : -10% to +10%), and reduced @entity50067 (change of @entity50067 :  <=-10%) were analyzed and compared. Improved @entity50067 occurred in 171 @entity1 and was associated with a superior long-term prognosis among all groups (P = 0.02 for all-cause mortality, P < 0.001 for @entity712 readmission). In Protocol 3, independent predictors of improved @entity50067 were analyzed, and baseline LV end-diastolic dimension (LVEDD) was identified as a powerful predictor in @entity697 @entity1 (P < 0.001). CONCLUSIONS: In @entity1 with @entity697 , posttreatment @entity50067 but not baseline @entity50067 had prognostic power. Improved @entity50067 was associated with superior long-term prognosis, and baseline LVEDD identified @entity1 who were more likely to have improved @entity50067 . Therefore, baseline @entity50067 should not be considered a relevant prognosis factor in clinical practice for @entity1 with @entity697 .
